| Style | Citing Format |
|---|---|
| MLA | Ehsani A, et al.. "Exploring the Cardiovascular Risk Factors in Patients With Hidradenitis Suppurativa: A Six-Year Cross-Sectional Study." Iranian Journal of Dermatology, vol. 28, no. 4, 2025, pp. 243-250. |
| APA | Ehsani A, Movahedi S, Nourmohammadpour P, Mohmmadabadi MK, Razavi Z, Ansari MS, Ehsani A, Nouri A, Rahimnia A (2025). Exploring the Cardiovascular Risk Factors in Patients With Hidradenitis Suppurativa: A Six-Year Cross-Sectional Study. Iranian Journal of Dermatology, 28(4), 243-250. |
| Chicago | Ehsani A, Movahedi S, Nourmohammadpour P, Mohmmadabadi MK, Razavi Z, Ansari MS, Ehsani A, Nouri A, Rahimnia A. "Exploring the Cardiovascular Risk Factors in Patients With Hidradenitis Suppurativa: A Six-Year Cross-Sectional Study." Iranian Journal of Dermatology 28, no. 4 (2025): 243-250. |
| Harvard | Ehsani A et al. (2025) 'Exploring the Cardiovascular Risk Factors in Patients With Hidradenitis Suppurativa: A Six-Year Cross-Sectional Study', Iranian Journal of Dermatology, 28(4), pp. 243-250. |
| Vancouver | Ehsani A, Movahedi S, Nourmohammadpour P, Mohmmadabadi MK, Razavi Z, Ansari MS, et al.. Exploring the Cardiovascular Risk Factors in Patients With Hidradenitis Suppurativa: A Six-Year Cross-Sectional Study. Iranian Journal of Dermatology. 2025;28(4):243-250. |
| BibTex | @article{ author = {Ehsani A and Movahedi S and Nourmohammadpour P and Mohmmadabadi MK and Razavi Z and Ansari MS and Ehsani A and Nouri A and Rahimnia A}, title = {Exploring the Cardiovascular Risk Factors in Patients With Hidradenitis Suppurativa: A Six-Year Cross-Sectional Study}, journal = {Iranian Journal of Dermatology}, volume = {28}, number = {4}, pages = {243-250}, year = {2025} } |
| RIS | TY - JOUR AU - Ehsani A AU - Movahedi S AU - Nourmohammadpour P AU - Mohmmadabadi MK AU - Razavi Z AU - Ansari MS AU - Ehsani A AU - Nouri A AU - Rahimnia A TI - Exploring the Cardiovascular Risk Factors in Patients With Hidradenitis Suppurativa: A Six-Year Cross-Sectional Study JO - Iranian Journal of Dermatology VL - 28 IS - 4 SP - 243 EP - 250 PY - 2025 ER - |